Oncomine™ Comprehensive Assay v3 GX

The Oncomine Comprehensive Assay v3 GX is a targeted, next-generation sequencing (NGS) assay that enables the detection of relevant SNVs, CNVs, gene fusions, and indels from 161 unique genes to help inform drug discovery research and clinical trial research programs. The assay kit provides reagents for library construction and four pool panels—two DNA and two RNA—of multiplex PCR primers for preparation of amplicon libraries to perform 16 sequencing reactions on formalin-fixed paraffin-embedded (FFPE) tumor samples.

Designed to go from hundreds down to a few relevant cancer drivers, this assay is part of a comprehensive workflow that enables NGS data analysis from as little as 10 ng of nucleic acid per pool. The assay is optimized for sequencing on the Ion Torrent Genexus Integrated Sequencer using the Ion Torrent Genexus GX5 Chip. The Genexus Integrated Sequencer performs library preparation, sequencing, analysis, and reporting in an automated workflow to deliver results in a single day. The multi-lane sequencing chip is designed to enable cost-effective processing of libraries.

Features of the Oncomine Comprehensive Assay v3 GX include:
• Analysis of variants across 161 genes
• Detection of SNVs, CNVs, gene fusions, and indels
• Robust performance from as little as 10 ng per pool (40 ng total) isolated from FFPE samples, including fine needle biopsies
• Characterized with molecular standards and controls
• Content driven by the Oncomine Knowledgebase and experienced scientists that helps assure coverage of key targets aligned to published evidence

From sample to answer
The Oncomine Comprehensive Assay v3 GX is part of an NGS workflow that helps researchers filter variant results from hundreds to just a few key cancer driver variants. Enabled by Oncomine informatics, this filtering, as well as the annotations from on-market labels, established guidelines (US-NCCN, US-FDA, EMSO, EMA), and global clinical trials, helps contextualize and interpret findings to move toward the answers you need. When combined with Oncomine Reporter Software, you can create reports that align labels, guidelines, and clinical trials to your results so you can focus on key drivers of cancer in your research.

The assay has been adopted by large-scale national clinical trial research programs, including NCI-MATCH (United States) and LC-SCRUM (Japan).

This kit takes advantage of:
• Proven Ion AmpliSeq chemistry
• Automated sample-to–report workflow using the Genexus System
• Scalable sequencing using the Genexus System
• Optimized Oncomine informatics